|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
51348680
???header.onlineuser??? :
676
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"powles"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2024-12 |
Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39
|
Kikuchi;E;Heijden, van der;M, S.;Valderrama, Perez;B;Gupta;S;Bedke;J;Shin;S, J.;Li;J-R;Guo;J;Danchaivijitr;P;Kanesvaran;R;Park;S, H.;Su;W-P;Kandori;S;Bae;W, K.;Wong;A, S.;Lu;J;Yu;X;Shetty;A;Bavle;A, A. A.;Powles;T, B. |
| 國立成功大學 |
2024-09 |
Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100
|
Grivas;P;Park;S, H.;Voog;E;Su;W-P;Demey;W;Fong;P, C.;Garcia;J, A.;Jacob;N;Gerhold-Ay;A;Tyroller;K;Hoffman;J;Bellmunt;J;Powles;T, B. |
| 國立成功大學 |
2024-02-1 |
Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study
|
Heijden, Van Der;Simon, Michiel;Powles;Thomas;Gupta;Shilpa;Bedke;Jens;Kikuchi;Eiji;Wit, De;Ronald;Galsky;Matt, D.;Duran;Ignacio;Necchi;Andrea;Retz;Margitta;Yu;Evan, Y.;Hoffman-Censits;Jean, H.;Iyer;Gopa;Park;Hoon, Se;Su;Wen-Pin;Parmar;Hema;Guan;Xuesong;Gorla;Rao, Seema;Moreno, Homet;Blanca;Valderrama;Perez, Begona |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
